Cell death biotech Kojin winds down, citing 4 funding challenges
Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.
Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.
